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Abstract: Autophagy is a complex process that controls the transport of cytoplasmic components
into lysosomes for degradation. This highly conserved proteolytic system involves dynamic and
complex processes, using similar molecular elements and machinery from yeast to humans. Moreover,
autophagic dysfunction may contribute to a broad spectrum of mammalian diseases. Indeed, in adult
tissues, where the capacity for regeneration or cell division is low or absent (e.g., in the mammalian
brain), the accumulation of proteins/peptides that would otherwise be recycled or destroyed may
have pathological implications. Indeed, such changes are hallmarks of pathologies, like Alzheimer’s,
Prion or Parkinson’s disease, known as proteinopathies. However, it is still unclear whether such
dysfunction is a cause or an effect in these conditions. One advantage when analysing autophagy in
the mammalian brain is that almost all the markers described in different cell lineages and systems
appear to be present in the brain, and even in neurons. By contrast, the mixture of cell types
present in the brain and the differentiation stage of such neurons, when compared with neurons in
culture, make translating basic research to the clinic less straightforward. Thus, the purpose of this
review is to describe and discuss the methods available to monitor autophagy in neurons and in
the mammalian brain, a process that is not yet fully understood, focusing primarily on mammalian
macroautophagy. We will describe some general features of neuronal autophagy that point to our
focus on neuropathologies in which macroautophagy may be altered. Indeed, we centre this review
around the hypothesis that enhanced autophagy may be able to provide therapeutic benefits in
some brain pathologies, like Alzheimer’s disease, considering this pathology as one of the most
prevalent proteinopathies.
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1. Introduction
The term “autophagy“ was first employed in cell biology around 20 years ago and led to an
explosion of information about a group of evolutionarily conserved genes (from yeast to humans)
involved in this process. Subsequently, autophagy was implicated in a wide range of homeostatic,
developmental and physiological events, and its deregulation has been linked to a wide spectrum of
mammalian diseases [1–5]. For instance, in relation to pathologies like Alzheimer’s (AD) or Parkinson’s
(PD) diseases, there is substantial evidence from patients and animal models that autophagy is
dysregulated [3,6]. A group of neuropathologies can be defined as proteinopathies, whereby defects in
autophagy contribute to the accumulation of peptide/protein aggregates. However, it remains unclear
whether such defects are the cause or effect of these pathologies.
In most mammalian cells, autophagy is classified into three general subtypes based on
how substrates are delivered to the lysosomal compartment: chaperone-mediated autophagy,
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microautophagy, and macroautophagy [7]. Our laboratory has focused on the role of macroautophagy
in neurons and in models of neurodegeneration. This process is essentially a constitutive mechanism
responsible for the turnover of cytoplasmic constituents of the cell, and it may be enhanced under
conditions of cell injury or nutritional deprivation in order to generate new substrates, thereby
complying with the cells energy demands and/or needs for cellular remodelling. Under such
conditions, a new double-membraned vacuole is created at phagophore assembly sites (PAS) and
is elongated under the direction of two ubiquitination-like reactions: the conjugation of Atg12 to
Atg5 by Atg7 proteins; and the conjugation of the cytosolic microtubule-associated light chain 30
(LC3-I) with phosphatidylethanolamine to form the membrane-associated LC3-II [8–10]. Together,
these proteins orchestrate the sequestering of cytoplasmic proteins into double-membrane-limited
autophagic vacuoles (AVs) or autophagosomes through autophagic adaptors, such as the cargo
receptors p62/SQSTM1 (sequestosome 1) and NBR1 (neighbour of Brca1 gene: [11,12]. Finally,
autophagosomes mature into single-membrane autophagolysosomes by fusing their outer membrane
with lysosomes, in which their contents are degraded by acidic lysosomal hydrolases and the lysosome
is then restored.
Autophagy involves dynamic and complex processes that are as yet not fully understood. Thus,
the purpose of this review is to describe and discuss the methods available to monitor autophagy in
neurons and in the mammalian brain, primarily focusing on mammalian macroautophagy (from now
on referred to simply as “autophagy”).
2. Methods for Monitoring Neuronal and Brain Autophagy
General methods to assay autophagy can be employed in neuronal systems, such as those
compiled elsewhere [13]. Numerous autophagy-related markers appear to be altered in different
neurodegenerative paradigms, including the conversion of LC3 to LC3-II, NBR1 and SQSTM1/p62
degradation, AMPK/mTORC1 activity, etc. Constitutive autophagy is particularly relevant in neurons
and in the brain as a part of normal physiology. Indeed, deficient autophagy caused by the mutation
of some proteins may cause neuronal cell death and/or neurodegeneration [14–17]. However, when
studying the role of autophagy in neurons, some specific issues cannot be ignored. On the one
hand, it is important to consider whether neuronal cell lines or primary cultures of neurons are
being analysed or if the brain itself is under study. On the other hand, it must be noted whether the
inhibitors/activators of autophagy used cross the blood–brain barrier (BBB) or not, influencing their
effect on the brain tissue. In addition, any potential toxicity of such compounds must also be taken
into account. Thus, drawing direct comparisons between neurons and the brain, in physiological or
pathological conditions, is not straightforward.
In addition to neurons, the central nervous system (CNS) is composed of astrocytes, microglia,
oligodendrocytes and endothelial cells, which in the case of the mouse brain exist in a ratio of about
3:1 glia/neuron [18]. Thus, the relative contribution of these cells has to be taken into account when
analysing brain tissue, for example in Western blots, and in many cases comparing data from neurons
or glia and brain tissue may be of interest. To gain more detailed information, primary neuron cultures
and complementary neuronal lines can be employed, cell systems that allow us to compare autophagic
responses under basal conditions or after manipulation with agents that modify autophagosome
formation or subsequent degradation steps.
3. Autophagy in Neuronal Systems: Neuroblastoma Cell Lines and/or Primary Neuronal Cultures
3.1. Basal Autophagy
Neurons are highly polarised cells with two morphological and biochemically distinct
compartments that contain specific proteins, a somato-dendritic and axonal compartment [19,20].
This polarity is essential for neuronal physiology, the structural integrity of which relies on efficient
proteostasis, and it seems that autophagy is particularly important in maintaining the axonal
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and dendritic components [21,22]. Autophagy is highly regulated in neurons, which contain few
autophagosomes, and may occur within the somato-dendritic compartment, in distal axons or at
synaptic terminals [23]. While the AVs that form in the somato-dendritic compartment cannot access
the axon, those formed in the distal axon can undergo retrograde transport to the soma [23–25]. Indeed,
there is evidence that the axon plays an important role in constitutive autophagosome generation
and transport [24,26], and that axonal transport is essential to clear damaged mitochondria [26] even
though their autophagic degradation may occur locally [27]. Indeed, amphisomes are exceptionally
common in the axons of neurons, as distal autophagosomes fuse with endosomes in the pathway
towards perinuclear lysosomes [15].
For many years neuron cell lines have been used as models to analyse autophagy (e.g., SH-SY5Y,
Neuro2A, SK-N-SH, etc.), although each have little or no capacity to polarise. Moreover, primary
neurons are usually cultured for just 3–5 days in vitro, which may not give them time to become
fully polarised. They needs around 2–3 weeks following the Banker´s lab procedure to be fully
polarised (for review see. {Bentley, 2016 #235}). It is important to note these differences between
neuronal cell lines and primary neurons, as each system may be distinct when assessing specific
parameters of autophagy. Indeed, some cell lines are aneuploid [28] or polyploid, which is likely to
also cause proteomic discompensation. Thus, comparative analyses of cell lines may identify different
responses, as reported for the inhibition of mTORC1 by rapamycin [29,30]. For instance, the degree
of autophagy in SH-SY5Y cells, as reflected by the conversion of LC3 to LC3II, appears to be modest
when triggered by mTORC1 inhibition, whereas it is more robust when we use the Calpain inhibitor,
Calpeptin (unpublished data). One explanation for this effect of rapamycin is that rapamycin mediated
inhibition of mTORC1 may also produce time-dependent mTORC2 inhibition in several tumour cell
lines, the latter representing an important regulator of Akt phosphorylation [31]. This effect is also
evident in primary neurons after 32 h in the presence of rapamycin (Figure 1), although it has not been
detected in vivo in brain tissue.
Similarly, when we analysed the basal status of PI3K-Akt-mTROC1 in these neuronal cell lines,
the activity of PDK1, Akt or mTORC differed when inferred from the phosphorylation of different
substrates. With respect to primary neurons, the degree of polarisation and the source of the neurons
may be important, although generally not much attention is paid to these issues. Indeed, some of
the elements in the PI3K-Akt pathway are expressed distinctly during maturation, not only during
brain development in vivo but also, in cell culture. This is this case of Akt activity, when inferred by
threonine 308 and serine 472/3 phosphorylation, and of the different Akt isoforms (as is more evident
in Akt2: [32], and as also occurs with LKB1-AMPK in different neuronal lineages. In conclusion, when
comparing data regarding autophagy in the brain and isolated neurons, it must be borne in mind that
this generally involves a comparison between mature and immature neurons, and that the influence of
the glia components present in vivo is absent in culture.
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Figure 1. Effects of pharmacological inhibition of mTORC1 on cultured primary cortical neurons. The 
status of the Akt-mTORC1 pathway was analysed after 30 min or 60 min of rapamycin incubation 
(A); orafter longer period of time (32 h) (B). C represent the control solvent and R represent rapamycin 
treatment, at each time point analysed. 
3.2. Activators and Inhibitors of Autophagy 
The second way to obtain information about autophagy in neurons and neuronal cell lines is 
through the use of activators or inhibitors that disturb the basal status. In terms of activators, different 
molecules have been used in diverse cell systems to activate basal autophagy, such as: mTORC1 
inhibitors (e.g., rapamycin); some PI3K-mTOR inhibitors like PI-103 or Torin 1; the Calpain inhibitor, 
Calpeptin; calcium channel blockers such as Nimodipine or Verapamil; or less specific activators like 
resveratrol, proteasome inhibitors (e.g., MG132) and ER stress drugs (e.g., Tunicamycin or Brefeldin 
A). Most of these compounds have some effect on neuronal cell lines or primary neurons, although 
to date there is little comparative data available. 
In terms of inhibitors, some drugs that disrupt the cytoskeleton have been reported to inhibit 
autophagy, such as Nocodazole or Taxol, and paradoxically some PI3K inhibitors like 3-
Methyladenine (3-MA), LY 294002 or Wortmannin. This contradiction arises from the fact that 
activators of autophagy like PI103 or Torin 1 (both PI3K-mTOR inhibitors), may generate similar a 
biochemical profile to that of LY 294002 or Wortmannin, such as inhibiting Akt or mTORC1 activity, 
Figure 1. Effects of pharmacological inhibition of mTORC1 on cultured primary cortical neurons.
The status of the Akt-mTORC1 pathway was analysed after 30 min or 60 min of rapamycin
incubation (A); orafter longer period of time (32 h) (B). C represent the control solvent and R represent
rapamycin treatment, at each time point analysed.
3.2. Activators and Inhibitors of Autophagy
T e second way to obtain information about autophagy in neurons and neur nal cell lines is
through the u e of activators or inhibitors that disturb the basal status. In terms of activators, different
molecules hav been used in div rse cell systems to activate basal autophagy, such as: mTORC1
inhibitors (e.g., rapa ycin); some PI3K-mTOR inhibitors like PI-103 or Torin 1; the Calpain inhibitor,
Calpeptin; calcium channel blockers such as Nimodipine or Verapamil; or less specific activators like
resveratrol, proteasome inhibitors (e.g., MG132) and ER stress drugs (e.g., Tunicamycin or Brefeldin
A). Most of these compounds have some effect on neuronal cell lines or primary neurons, although to
date there is little comparative data available.
In terms of inhibitors, some drugs that disrupt the cytoskeleton have been reported to inhibit
autophagy, such as Nocodazol or Tax l, and paradoxically some PI3K inhibitors like 3-Methyladenine
(3-MA), LY 294002 r W r mannin. This contradictio arises from t e fact tha activators of autophagy
like PI103 or Torin 1 (both PI3K-mTOR inhibitors), may generate similar a biochemical profile to that of
LY 294002 or Wortmannin, such as inhibiting Akt or mTORC1 activity, etc. However, these compounds
were reported to have the opposite effect in other cell systems: for instance, LY 294002 generates a
neuronal polarity defect in our hands that cannot be reproduced by the new PI3K class I inhibitor
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GDC0941, or by a combination of this PI3K inhibitor and rapamycin [33]. We also detected that the
high concentration of 3-MA used when it was described as an inhibitor of PI3K class III and autophagy
may also provoke the inhibition of PI3K class I [33].
The way in which autophagic flux is estimated should also be borne in mind. Several compounds
have been used to this end, like the vacuolar H+-ATPase inhibitor Bafilomycin A1, Chloroquine
diphosphate or NH4Cl, which will directly affect lysosomal pH, prevent acidification and activate
proteases. Alternatively, several general protease inhibitors have been used to block lysosomal
degradation, such Pepstatin A or Leupeptin [13,34].
3.3. Specific Methods to Monitor Autophagy in Neuronal Systems
Several methods can be used to monitor autophagy in neuronal and non-neuronal cells, although
some particularities of each cell type must be taken into account. Firstly, autophagic responses to
different stimuli may vary not only between cell types or between dividing and non-dividing cells but
also within a specific cell type depending on its state of confluency/differentiation and/or the culture
medium or conditions. The most common methods to monitor autophagy in neuronal cell systems are
reviewed below:
Transmission electron microscopy (TEM) can be used to characterise the presence of specific
autophagic structures. However, when primary neurons or differentiated neuroblastoma cell lines are
harvested in culture, their projections or neurites are disrupted, which alters the cell’s morphology.
Moreover, some confusion may be generated if differential studies are carried out on neuronal
compartments, unless the presence of the nucleus is used to ensure correct identification of the soma.
To avoid such issues, samples can be prepared on the surface of coverslips [35]. In aged post-mitotic
cells like neurons, the presence of residual bodies has been reported, such as a lysosome subtype
that reflects unsuccessful incomplete autolysosomal digestion that can be readily distinguished by
TEM [13,36].
LC3-I to LC3-II conversion can be readily assessed in Western blots due to the distinct
electrophoretic mobility of these isoforms, or through the LC3 dots that can be detected by
immunofluorescence. A high ratio of LC3-I to LC3-II is common in neuronal cells and only a
slight increase in LC3-II occurs on inducing autophagy by nutrient deprivation or with chemicals.
This feature has been related to an efficient basal autophagic flux, where the enhanced formation of
autophagosomes is associated with their rapid clearance by fusion with lysosomes [23]. However,
blockage of lysosomal fusion and degradation after different pro-autophagic stimuli only provokes a
mild increase in autophagy in our hands, contrasting with the notable increase observed in tumour
cell lines. In neuronal cultures, it is especially important to adjust the time and concentration of
exposure to some lysosomal inhibitors (e.g., bafilomycin A1) in order to avoid cytotoxicity, and the
results should be contrasted to those achieved through other strategies. Given the tight regulation
and time restrictions associated with primary neuronal cultures, results based on LC3 conversion may
be confusing. As a complementary strategy, assays of lysosomal activity can be performed to define
their degradation capacity. In our hands, the lysosomal activity of neuronal cultures can be efficiently
measured by assessing cathepsin activity or by in vivo monitoring of the pH-dependent intensity of
fluorescent acidotropic dyes.
To avoid the use of lysosome inhibitors, autophagic flux can also be determined via the expression
of GFP-LC3B [37] or a tandem mCherry/mRFP-GFP tagged LC3 construct [38]. The assay of the former
is based on the LC3 part of the chimera being more sensitive to degradation than GFP, such that both
elements can be monitored in Western blots to estimate lysis by lysosomes. The latter assay is based
on the GFP fluorescent signal being more sensitive to the acidic conditions of the lysosome, whereas
mCherry or mRFP is more stable. Accordingly, the co-localisation of both GFP and mCherry/mRFP
fluorescence corresponds to a phagophore or an autophagosome, whereas an mCherry/mRFP signal
independent of GFP indicates lysosomal fusion. However, the problems associated with neuronal
transfection make it necessary to optimise the protocols when using these techniques. In our hands,
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neuronal cells show very variable expression of the tandem mRFP-GFP-LC3 construct in culture and
very weak mRFP signals, with or without GFP, consistent with the smaller number of autophagic
vesicles in neurons, which makes the interpretation of these assays more difficult. More recently,
an alternative construct, pHluorin-mKate2-LC3, has been reported that is suitable for monitoring
autophagic structures {Tanida, 2014 #320} {Tanida, 2017 #319}.
Although several methods have been described to determine autophagic flux by flow cytometry,
this technique is not appropriate for neuronal cells with long projections that would be disrupted
when detached from the surface. This technique could be used for non-differentiated neuroblastoma
cell lines, such as SH-SY5Y, although the preparation of adherent cells for such assays may induce
secondary autophagy [13].
As neurons are highly dependent on healthy mitochondria, mitophagy has been extensively
studied in these cells. However, it must be taken into account that certain types of mitophagy induced
by BNIP3L/NIX are dependent on gamma-aminobutyric acid receptor-associated protein (GABARAP)
and they are less dependent on LC3 proteins [39,40]. Indeed, an enrichment of GABARAP has been
described in certain neuronal areas [41] and thus, studying this mammalian homologue of the Atg8
subfamily should be considered.
The rate of autophagic degradation promoted by autophagy can be assessed by studying some
adaptor proteins specifically bound to autophagosomes in Western blots. In neurons, measuring
the autophagic adaptor NBR1 in flux experiments with lysosomal inhibitors reflects LC3-II turnover,
making this a useful complementary tool to assay the rate of degradation. This analysis can be also
done with the better studied autophagic adaptor p62/SQSTM1, although the high levels of this protein
and its long half-life make it harder to appreciate significant differences with the short exposures to
lysosomal inhibitors. However, these features make p62/SQSTM1 an optimal marker to assay any
increase in the rate of degradation in our neuronal system after long-term treatment with an inducer
of autophagy.
4. Autophagy in Mouse Models
The methods available to monitor autophagic flux in vivo have been poorly developed and the
obstacles associated with drug bioavailability in the CNS make this an even more difficult task.
4.1. Methods to Monitor Autophagy In Vivo
Electron microscopy (EM). Dystrophic neurites in some neurodegenerative diseases are rich
in autophagic structures that are enriched in hydrolases and that contain partially digested
amorphous substrates. These structures are derived from the autolysosomes and damaged lysosomes
(“lysosophagy”) characteristic of active autophagy [3]. EM enables the transcellular degradation of
mitochondria (“transmitophagy”) to be visualised in the nervous system, as described when astrocytes
degrade an axon-derived protrusion containing damaged mitochondria [42]. Like any ex vivo tissue,
the brain should be fixed immediately to avoid changes in autophagy, and thus perfusion fixation
is recommended.
LC3-I to LC3-II conversion. According to our data, LC3-I is much more abundant than LC3-II
in brain tissue [43]. To analyse this conversion, the membrane fraction of a cell lysate may need to
be purified for immunoblot analysis [44]. To determine the autophagic flux, degradation should be
blocked, although most of the usual drugs employed in cell culture have some toxic effects and they
must be able to cross the BBB when used in vivo. Leupeptin crosses the blood—retinal barrier and
blocks degradation in the retina after intraperitoneal (ip) injection, constituting an interesting model to
study autophagy in the CNS [45]. Other strategies involve the intracerebroventricular (icv) injection
of leupeptin [46] or the ip injection of the lysosomotropic dye monodansylcadaverine (MDC) that
co-localises with LC3 dots [47,48].
In vivo transgenesis. Transgenic mice represent an alternative method to analyse autophagy and
indeed, GFP-LC3 transgenic mice have been employed to assess the autophagic flux in Western blots
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of postmortem tissue, the cleavage of GFP-LC3 releasing free GFP [13,43]. However, the accumulation
of free GFP in the mouse brain is minimal after inducing autophagy but significant when this
process is blocked after traumatic brain injury [49]. Multiple mutant Atg mice have been developed
(KOs) in which these proteins are knocked down in the nervous system [17,50–57]. In addition,
to limit the transfection of autophagy-related constructs into the CNS, adeno-associated virus can be
injected icv into new-born mice. This approach has been used to achieve the in vivo expression of
mCherry-GFP-LC3 [58,59] or of Mito-EGFP-mCherry to specifically study mitophagy [42].
4.2. Autophagy in Mouse Models of Neurodegeneration
Alterations to autophagy in the nervous system have been associated with some
neurodevelopmental, neurometabolic and neurodegenerative disorders [60–63]. Moreover, in many
cases, these defects in autophagy are considered drivers of disease pathogenesis rather than secondary
consequences. Indeed, excess autophagy may be detrimental when associated with specific acute
neural damage [62–64], whereas deficient autophagy might lead to the accumulation of misfolded
proteins, which hinders normal cell physiology. Such conditions are considered proteinopathies, as is
the case of most late-onset neurodegenerative diseases like AD, PD and Huntington’s disease (HD:
the role of autophagy in many neurological diseases has been reviewed recently in [65]). Autophagic
and lysosomal activity diminishes with age, and lower rates of degradation would lead to the
accumulation of dysfunctional proteins and organelles, as well as to axonal dystrophy. As such,
it is not surprising that these features are more prominent in age-related diseases like AD, where
autophagic vesicles accumulate within dystrophic neurites near senile plaques [66–68]. Accordingly,
upregulation of autophagic degradation in some animal models of different neurodegenerative
diseases has been seen to have protective effects [50,65,69,70]. Here, we have focused on the strategies
employed to modulate autophagy in mouse models of AD, one of the most studied autophagy-related
proteinopathies (again, we refer the reader to a recent review to obtain information on the role of
autophagy in other neurodegenerative diseases: [65]).
5. Alzheimer’s Disease (AD)
Alzheimer’s disease is the most common neurodegenerative disorder and is considered a
proteinopathy that is characterised by the accumulation of deposits of aggregated amyloid-beta
(Aβ: Senile plaques) and hyperphosphorylated tau (Tangles). There are data indicating that autophagy
is impaired in this pathology and the accumulation of autophagic vesicles within dystrophic neurites
in the brain suggests a progressive deregulation of protein turnover. Several factors associate AD with
dysfunctions in autophagy, such as the accumulation of amyloid and tau aggregates that might saturate
the clearance system, or mutations in PS1 and PICALM that could affect lysosome activity or different
steps in autophagy, respectively [60,65,71]. Alternatively, mTOR hyperactivation in AD models seems
to be caused by Aβ hindering autophagy and consequently, contributing to the accumulation of Aβ
and tau [72,73].
Autophagic markers like LC3-II, p62 or NBR1 have been reported to be modified in postmortem
brains from AD patients and in AD animal models. Numerous studies in mice models of AD have
shown a relationship between autophagy and the hallmarks of AD, Aβ or tau aggregates. Genetic
deletion of the pro-autophagic protein Becn-1 aggravates the AD pathology, whereas its enhancement
or an improvement in lysosomal function reduces the amyloid load (Table 1: [74–77]. Conversely,
pharmacological activation of autophagy has been reported to have positive effects in several AD
mouse models (Table 1). Rapamycin is the most often used inducer of autophagy and inhibits mTORC1
in vivo. In our hands, rapamycin reduces amyloid levels (unpublished data), as observed in other
mouse models of AD [72,78,79], although contrasting results not related to autophagy have also
been described [80]. In recent years, many compounds that induce autophagy or improve lysosomal
clearance have shown promising therapeutic benefits in diverse AD mouse models, and some have
already been FDA approved (reviewed in Table 1, though surely incomplete). Some of these also
Cells 2017, 6, 25 8 of 16
induce AMPK/mTORC1-dependent autophagy, such as latrepirdine [81] or resveratrol [82], whereas
others promote mTORC1-independent autophagy, for example through the inhibition of HDAC6
with Tubastatin A/ACY-1215 [83], the inhibition of Calpain with Calpeptin or BDA-410 [84], or the
inhibition of some tyrosine kinases [85,86].
In addition to the induction of autophagy, the restoration of lysosomal activity is another related
therapeutic target for age-associated proteinopathies. Accordingly, some compounds have improved
the clearance of amyloid deposits by enhancing the activity of lysosomal proteases, for example
Cathepsin B [87], or by restoring acidification through GSK3 inhibition [88]. While most of the data
available suggests that enhancing autophagy may improve amyloid degradation, an associated rise
in amyloid production has also been described (Table 1). According to this hypothesis, an increase
in autophagic vesicle load confers an optimal environment for amyloidogenic processing of amyloid
precursor protein (APP) [2,89]. Accordingly, we think that the data currently available suggest that
more work should be carried out to clarify whether alternative methods to enhance neuronal autophagy
may have additional therapeutic benefits in pathologies like AD or similar proteinopathies.
Table 1. Summary of data using different compounds in AD models. The putative mechanism,
connecting or not autophagy, and the therapeutic effects were indicated.
AD Mouse Model Treatment Molecular Mechanism Phenotypic Effect Ref.
T41 mice
(mThy-1-hAPP751; APP
V171I,K670M/N671L)
Genetic deletion of
Becn-1 Reduced autophagy
Increased amyloid-β levels
and deposits.
Increased
neurodegeneration.
[74]
Lentivirus-mediated
expression of Becn-1 Reduced Aβ levels
hAPP-J20 mice Genetic deletion ofcystatin C
Increased lysosomal
cysteine proteases activity
Rescued autophagic-
lysosomal pathology
Reduced Aβ levels and
Aβ-associated cognitive
deficits and behavioural
abnormalities
[75]
TgCRND8 mice (APP
K670M, M671L, V717F)
Genetic deletion of
cystatin B
Increased lysosomal
cysteine proteases activity
Rescued autophagic-
lysosomal pathology
Reduced amyloid-β40 and
-β42 levels and prevented
the development of learning
and memory deficits
[76]
hAPP-J20 mice
Lentivirus-mediated
expression of
Cathepsin B
C-terminal truncation of
Aβ42
Reduced pre-existing
amyloid deposits [77]
APP/PS1
(B6C3-Tg(APPswe,
PSEN1dE9)85Dbo/J)
Genetic deletion of
one allele of
Cathepsin D
Non reduced APP
processing or degradation No changes in Aβ levels [90]
3× Tg-AD mice
(APPSwe /tauP301L/
PS1 knock-in)
Rapamycin mTORC1 inhibitionautophagy induction
Improved learning and
memory deficits and
reduced amyloid-β and
tau pathology
[72]
PDAPP mice (hAPP(J20)) Rapamycin
mTORC1 inhibition
autophagy induction
chaperone levels increase
Improved cognitive deficits
and decreased
amyloid-β42 levels
[78,79]
Tg2576 mice Rapamycin mTORC1 inhibitioninhibition of ADAM10 Increased amyloid-β levels [80]
TgCRND8 mice (APP
K670M, M671L, V717F) Latrepirdine
mTORC1 inhibition
autophagy induction
Improved learning
behaviour and reduced
amyloid-β42 and
a-synuclein levels
[81]
APP/PS1
(B6C3-Tg(APPswe,
PSEN1dE9)85Dbo/J)
Resveratrol AMPK activationAutophagy induction
Reduced amyloid-β40 and
-β42 levels [82]
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Table 1. Cont.
AD Mouse Model Treatment Molecular Mechanism Phenotypic Effect Ref.
APPswe/PS1dE9 Tubastatin A andACY-1215
HDAC6 inhibition
facilitated autophagic
clearance of Aβ and
hyperphosphorylated tau
alleviated behavioural
deficits, altered Aβ load,
and reduced tau
hyperphosphorylation
[83]
APP/PS1
(B6C3-Tg(APPswe,
PSEN1dE9)85Dbo/J)
APPSwInd
Z-Phe-Ala-
diazomethylketone
(PADK)
Increased Cathepsin B
protein levels and activity
Truncation of Aβ42
Reduced Aβ levels and
Aβ-associated behavioural
and synaptic deficits
[87]
APP/PS1 mice (APP
K670M and M671L; PS1
M146L)
BDA-410
Calpain inhibition *
Restoration of normal
phosphorylation levels
of CREB
Improved spatial-working
and associative fear
memories
[84]
Tg6799 (APP
K670N/M671L, I716V,
V717I; PS1
M146L/L286V)
L803-mts
GSK3 a/b inhibition
Restoration of lysosomal
acidification
Reduced Aβ burdens [88]
AβPPSwe/PS1A246E Lithium
GSK3β inhibition
Attenuated the autophagy
activation, reducing APP
processing
Reduced Aβ total levels
and deposits.
Improved spatial learning
and memory abilities.
[91]
APP/PS1 mice Trehalose
Altered the conformation
Aβ to prevent its interaction
with membranes
Autophagy induction
Reduced Aβ deposits, and
total Aβ40 levels.
Improved spatial memory
and learning ability.
[92]
P301S tau mice Trehalose Autophagy induction Reduced tau levels anddeposits. [93]
Tg2576 mice (APP Swe,
K670N, M671L) Trehalose Autophagy induction
Reduced Aβ and tau
deposits. [94]
Tg6799 mice (APP
K670N/M671L, I716V,
V717I; PS1
M146L/L286V)
Metformin
AMPK activation and
mTORC1 inhibition induces
an abnormal accumulation
of autophagosomes,
promoting APP processing
Increased generation
of Aβ [84]
Tg-APP mice (APP 770
isoform K670N/M671L,
E693Q, D694N)
Tyrosine kinase
inhibitors (TKIs)
(nilotinib, bosutinib)
Increased parkin-Beclin1
interaction
Autophagy induction
Reduced Aβ levels.
Cognitive improvement. [85,86]
3 × Tg-AD mice
(APPSwe/tau
P301L/PS1 M146V)
Nicotinamide
Increased NAD+
biosynthesis, promoting
autophagy and lysosomal
acidification
Reduced Aβ and
hyperphospholylated tau
levels.
Cognitive improvement.
[95]
APP/PS1 mice (APP
K594N/M595L;
PS1-dE9)
3-benzyl-5-((2-
nitrophenoxy)
methyl)-dihydrofuran-
2(3 H)-one (3BDO)
Increased levels of insulin
degrading enzyme and
neprilysin.
Suppressed autophagy via
mTOR pathway
Reduced Aβ levels.
Prevented AD-like
cognitive deficits.
[96]
APP/PS1 mice (APP
Swe/PSEN1dE9) Carbamazepine
Autophagy induction
unlikely via mTOR
inhibition
Reduced amyloid plaque
burden and Aβ42 levels.
Alleviated spatial learning
and memory deficits.
[97]
3× Tg-AD mice
(APPSwe/tau
P301L/PS1 M146V)
GTM-1 Autophagy induction
Reduced Aβ levels and
deposition.
Alleviated spatial learning
and memory deficits.
[98]
APP-OSK mice
Tg2576 mice
Tau609 mice
Rifampicin
Inhibition of oligomer
formation preventing
protein accumulation and
autophagy dysfunction.
Reduced Aβ oligomer
accumulation and tau
hyperphosphorylation.
Improved spatial memory.
[99]
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Table 1. Cont.
AD Mouse Model Treatment Molecular Mechanism Phenotypic Effect Ref.
APP/PS1 mice (APP
Swe/PSEN1dE9) LX2343
Suppression of
JNK-mediated
phosphorylation of
APP(Thr668), and thus
APP processing.
PI3K/AKT/mTOR
inhibition and induction
of autophagy.
Reduced Aβ levels
and deposits.
Alleviated spatial learning
and memory deficits.
[100]
3 × Tg-AD mice
(APPSwe/tau
P301L/PS1 M146V)
Berberine Autophagy induction.
Reduced Aβ levels and
deposits.
Improved spatial learning
capacity and
memory retention.
[101]
3× Tg-AD mice
(APPSwe/tau
P301L/PS1 M146V)
Selenomethionine
(Se-Met)
Akt activation and
GSK3β inhibition.
Autophagy induction
(AMPK-mTORC1
dependent).
Reduced total and
hyper-phosphorylated tau.
Improved spatial memory
[102]
* Calpain inhibition has been described as an mTORC1-independent mechanism to induce autophagy [103–105],
although no relationship has been studied in this report.
Cortical neurons from mice were treated with rapamycin 3 h after plating, and they were
maintained in the presence of rapamycin for short (30 min and 60 min: “A”) or long periods (32 h:
“B”), using DMSO alone as a control. Cell extracts were obtained and analysed in Western blots
probed with antibodies against some elements of the Akt-mTORC1 pathway, phosphorylated and total
proteins such as Akt, S6K1, S6, etc. GAPDH and beta-actin were used as controls of loading. Note that
Akt-pSer472/3 is still evident 30 min or 60 min after rapamycin inhibition (asterisk in A), whereas it is
almost completely lost after 32 h in the presence of rapamycin (arrows in B).
6. Conclusions
We try to describe and discuss some methods available to monitor autophagy in neurons and in the
mammalian brain taking into account the troubles to correlate brain to primary neurons. We dedicated
this review primarily on mammalian macroauophagy that we consider highly important in many
neuropathologies, such as Parkinson, Alzheimer’s disease or Huntington where the accumulation
of peptide/protein strongly suggest an autophagy dysfunction. We focused our review around the
hypothesis that enhanced autophagy may be able to provide therapeutic benefits in Alzheimer’s
disease, considering this pathology as one of the most prevalent proteinopathies.
The data summarized strongly suggested that we are far away for understanding of how
autophagy is regulated in neurons or in the brain. We have clear data that in some cases,
such as rapamycin, the therapeutic effect on amyloidosis reported may be via of mTROC1
inhibition/autophagy enhanced however not all compound modifying mTORC1 activity appear
to directly correlated with similar effects. Finally more work have to be done to clarify whether the
modification of autophagy always correlated with a reduction on amyloidosis.
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